PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry

Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry

by PublicWire
April 26, 2019
in Medical
Reading Time: 3 mins read
0

ORLANDO, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE – – Immune Therapeutics, Inc. (OTCQB: IMUN), a late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today announced that the Company’s multi-pronged growth strategy, which includes the pursuit of the multi-billion dollar pet care industry, was favorably mentioned in an article published today in Forbes Magazine. (Link to Story: Can Cats and Dogs Help Reverse Marijuana’s Stigma?)

The article, which also includes excerpts from an interview with the Company’s CEO, Noreen Griffin, classifies Immune Therapeutics as a ‘pioneering biopharmaceutical company that recognized the massive potential in the growing animal health market and has introduced a partnership to tap into it’ (referring to the Company’s recent 10% acquisition of Cytocom, Inc. which included exclusive rights to Lodonal™ and Met-Enkephline for the treatment of pets in the United States).

“Today’s positive coverage of Immune Therapeutics by such a well-respected and internationally distributed publication, such as Forbes, is a yet another indication that Immune has truly embarked on a new era of growth and expansion as we look towards the bright future that lays ahead,” said Ms. Griffin. “We believe the ongoing progress we are making in Africa, along with the recent filings of new patents and the exclusive revenue channels stemming from the pet care industry will further strengthen Immune Therapeutics, Inc.’s market position,” concluded Ms. Griffin.

Immune Therapeutics Gains Exclusive Drug Rights for Booming Pet Care Industry
The global market for animal medication is projected to reach $44.4 billion by 2022, driven by increasing investments in animal drug development in response to unmet animal health needs and developments in veterinary diagnostics and services. Overall, 68% of U.S. households, or about 84.6 million homes, own a pet, according to the APPA. Dogs and cats are the most popular pets, followed by freshwater fish and birds.

ABOUT IMMUNE THERAPEUTICS, INC.

Immune Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of highly innovative immunotherapies. Immune Therapeutics is actively developing T-Activation immunotherapies to achieve immunomodulation in patients both human and pets with autoimmune and inflammatory disease, cancer and infectious diseases.

Forward-Looking Statements

This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.

Tags: ForbesImmune TherapeuticsIMUNpet-care
Previous Post

Attis Industries Continues to Improve Balance Sheet and Stockholders Equity

Next Post

Bespoke Extracts Announces Launch of Wholesale CBD Division, Among Other Key Marketing and Business Developments

PublicWire

At PublicWire, we know the vast majority of all investors conduct their due diligence and get their news online in a variety of ways including email, social media, financial websites, text messages, RSS feeds and audio/video podcasts. PublicWire’s financial communications program is uniquely positioned to reach these investors throughout the U.S. and Canada as well as on a global scale.

Related Posts

Medical

FDA advisory panel recommends Moderna, Johnson & Johnson vaccine booster shots

October 18, 2021
0
Medical

Walgreens invests $5.5B to accelerate new healthcare business segment

October 18, 2021
0
Medical

Mayo Clinic to study respiratory muscle training as long COVID treatment

October 18, 2021
0
Medical

Anthem, Providence tap Vim for value-based care platform deployment

October 25, 2021
0
Medical

Healthcare lost 17,500 jobs in September amid ongoing labor shortage

October 25, 2021
0
Medical

Cigna divests life, accident and supplemental benefits businesses for $5.75B

October 25, 2021
0
Next Post

Bespoke Extracts Announces Launch of Wholesale CBD Division, Among Other Key Marketing and Business Developments

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.